{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:56:29Z","timestamp":1789588589118,"version":"build-2803163510"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.vaccine.2025.127892","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T17:39:21Z","timestamp":1761673161000},"page":"127892","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The relationship between the immunogenicity and reactogenicity of vaccines: A narrative review"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9319-7740","authenticated-orcid":false,"given":"Daniel J.","family":"Gromer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3755-7771","authenticated-orcid":false,"given":"Suha","family":"Kalash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1189-0777","authenticated-orcid":false,"given":"Ralph","family":"Tanios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2512-7919","authenticated-orcid":false,"given":"Nadine","family":"Rouphael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127892_bb0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how\u2019s and what\u2019s of vaccine reactogenicity","volume":"4","author":"Herv\u00e9","year":"2019","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2025.127892_bb0010","series-title":"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials","author":"Center for Biologics Evaluation and Research","year":"2024"},{"key":"10.1016\/j.vaccine.2025.127892_bb0015","first-page":"1099","article-title":"A study of the immunogenicity of smallpox vaccines","volume":"20","author":"Soloviev","year":"1959","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2025.127892_bb0020","doi-asserted-by":"crossref","first-page":"7743","DOI":"10.1016\/j.vaccine.2007.09.023","article-title":"Tail scarification with Vaccinia virus Lister as a model for evaluation of smallpox vaccine potency in mice","volume":"25","author":"Melamed","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127892_bb0025","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2020-002993","article-title":"BCG skin reactions by 2 months of age are associated with better survival in infancy: a prospective observational study from Guinea-Bissau","volume":"5","author":"Schaltz-Buchholzer","year":"2020","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.vaccine.2025.127892_bb0030","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.tube.2009.03.002","article-title":"Mapping the global use of different BCG vaccine strains","volume":"89","author":"Ritz","year":"2009","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.vaccine.2025.127892_bb0035","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1016\/j.vaccine.2015.02.056","article-title":"Variation of growth in the production of the BCG vaccine and the association with the immune response. An observational study within a randomised trial","volume":"33","author":"Biering-S\u00f8rensen","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127892_bb0040","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/bmj.1.5438.817","article-title":"Vaccination against measles: a study of clinical reactions and serological responses of young children. a report to the medical council by the measles vaccines committee","volume":"1","author":"Norrby","year":"1965","journal-title":"Br Med J"},{"key":"10.1016\/j.vaccine.2025.127892_bb0045","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4161\/hv.2.5.3246","article-title":"Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad)","volume":"2","author":"Kuter","year":"2006","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2025.127892_bb0050","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1017\/S0950268818001474","article-title":"Post-immunisation fever and the antibody response to measles-containing vaccines","volume":"146","author":"Carazo Perez","year":"2018","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2025.127892_bb0055","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1080\/21645515.2020.1849520","article-title":"Genetic associations with a fever after measles-containing vaccines","volume":"17","author":"Klein","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127892_bb0060","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/art.1780220414","article-title":"Studies on vaccine-induced rubella arthritis. Serologic findings before and after immunization","volume":"22","author":"Tingle","year":"1979","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.vaccine.2025.127892_bb0065","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/oxfordjournals.aje.a113776","article-title":"Immunologic responsiveness and safety associated with the Coccidioides immitis spherule vaccine in volunteers of white, black, and Filipino ancestry","volume":"119","author":"Williams","year":"1984","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2025.127892_bb0070","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1542\/peds.85.3.294","article-title":"Longitudinal study of adverse reactions following diphtheria-tetanus-pertussis vaccine in infancy","volume":"85","author":"Long","year":"1990","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2025.127892_bb0075","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1542\/peds.96.3.584","article-title":"Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines","volume":"96","author":"Christy","year":"1995","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2025.127892_bb0080","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1097\/01.inf.0000190028.96152.46","article-title":"A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial","volume":"24","author":"Scheifele","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2025.127892_bb0085","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/0264-410X(94)00082-X","article-title":"Booster vaccination against diphtheria and tetanus in man. Comparison of calcium phosphate and aluminium hydroxide as adjuvants--II","volume":"13","author":"Aggerbeck","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127892_bb0090","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1017\/S095026881800242X","article-title":"Predictors of the immune response to booster immunisation against tetanus in Czech healthy adults","volume":"146","author":"Petr\u00e1\u0161","year":"2018","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2025.127892_bb0095","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj1701","article-title":"A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa","volume":"9","author":"Huttner","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2025.127892_bb0100","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.vaccine.2019.02.015","article-title":"Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans","volume":"37","author":"Burny","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127892_bb0105","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3389\/fimmu.2017.00943","article-title":"Different adjuvants induce common innate pathways that are associated with enhanced adaptive responses against a model antigen in humans","volume":"8","author":"Burny","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127892_bb0110","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/22221751.2021.1891002","article-title":"Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response","volume":"10","author":"Zhuang","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2025.127892_bb0115","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1093\/infdis\/jiab536","article-title":"Association between immunogenicity and reactogenicity: a post Hoc analysis of 2 phase 3 studies with the adjuvanted recombinant zoster vaccine","volume":"226","author":"Callegaro","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127892_bb0120","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/jmv.1890030305","article-title":"The absence of differences in cellular immunity in elderly individuals with and without delayed local cutaneous reactions to influenza vaccine","volume":"3","author":"Roberts","year":"1979","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2025.127892_bb0125","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1016\/j.vaccine.2015.05.008","article-title":"Proinflammatory cytokine responses correspond with subjective side effects after influenza virus vaccination","volume":"33","author":"Christian","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127892_bb0130","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1097\/INF.0000000000001949","article-title":"Impact of fever and antipyretic use on influenza vaccine immune reponses in children","volume":"37","author":"Li-Kim-Moy","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2025.127892_bb0135","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/infdis\/jiaa255","article-title":"Comparative reactogenicity of enhanced influenza vaccines in older adults","volume":"222","author":"Cowling","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127892_bb0140","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3390\/vaccines12070809","article-title":"The Relationship between Immunogenicity and Reactogenicity of Seasonal Influenza Vaccine Using Different Delivery Methods","volume":"12","author":"Gromer","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127892_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.894277","article-title":"Analysis of immunization time, amplitude, and adverse events of seven different vaccines against SARS-CoV-2 across four different countries","volume":"13","author":"Romero-Ibarguengoitia","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127892_bb0150","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3390\/vaccines10071139","article-title":"Analysis of immunization, adverse events, and efficacy of a fourth dose of BNT162b2 vaccine in health workers in Mexico, a pilot study","volume":"10","author":"Romero-Ibarguengoitia","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127892_bb0155","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.cmi.2022.07.002","article-title":"Association between IgG antibody levels and adverse events after first and second Bnt162b2 mRNA vaccine doses","volume":"28","author":"Braun","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2025.127892_bb0160","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.cmi.2023.05.028","article-title":"Association between reactogenicity and immunogenicity after BNT162b2 booster vaccination: a secondary analysis of a prospective cohort study","volume":"29","author":"Jorda","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2025.127892_bb0165","article-title":"Association of self-reported systemic reactions following SARS-CoV-2 vaccination with immunological response in the danish national cohort study of effectiveness and safety of SARS-CoV-2 vaccines (ENFORCE)","volume":"10","author":"Bannister","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127892_bb0170","doi-asserted-by":"crossref","first-page":"9264","DOI":"10.1038\/s41598-023-36429-1","article-title":"Association of systemic adverse reaction patterns with long-term dynamics of humoral and cellular immunity after coronavirus disease 2019 third vaccination","volume":"13","author":"Yoshida","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.127892_bb0175","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1016\/j.vaccine.2021.07.067","article-title":"Association of total and neutralizing SARS-CoV-2 spike -receptor binding domain antibodies with epidemiological and clinical characteristics after immunization with the 1st and 2nd doses of the BNT162b2 vaccine","volume":"39","author":"Michos","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127892_bb0180","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1001\/jamainternmed.2021.4580","article-title":"Association of vaccine type and prior SARS-CoV-2 infection with symptoms and antibody measurements following vaccination among health care workers","volume":"181","author":"Debes","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.vaccine.2025.127892_bb0185","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/cid\/ciac780","article-title":"Associations of immunogenicity and reactogenicity after severe acute respiratory syndrome coronavirus 2 mRNA-1273 vaccine in the COVE and TeenCOVE trials","volume":"76","author":"Siangphoe","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127892_bb0190","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/cid\/ciac840","article-title":"Multiparametric prediction models for coronavirus disease 2019 vaccine selection: results of a comparative population-based cohort study","volume":"76","author":"Sieghart","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127892_bb0195","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3390\/vaccines9101063","article-title":"Reactogenicity correlates only weakly with humoral immunogenicity after COVID-19 vaccination with BNT162b2 mRNA (Comirnaty\u00ae)","volume":"9","author":"Held","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127892_bb0200","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/acr.24894","article-title":"Reactogenicity of the messenger RNA SARS-CoV-2 vaccines associated with immunogenicity in patients with autoimmune and inflammatory disease","volume":"74","author":"Yang","year":"2022","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.vaccine.2025.127892_bb0205","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.vaccine.2022.02.025","article-title":"Relation of fever intensity and antipyretic use with specific antibody response after two doses of the BNT162b2 mRNA vaccine","volume":"40","author":"Tani","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127892_bb0210","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2024.29.25.2300585","article-title":"Association between adverse events after COVID-19 vaccination and anti-SARS-CoV-2 antibody concentrations, the Netherlands, May 2021 to November 2022: a population-based prospective cohort study","volume":"29","author":"Holwerda","year":"2024","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2025.127892_bb0215","doi-asserted-by":"crossref","first-page":"7317","DOI":"10.1016\/j.vaccine.2023.10.037","article-title":"The association between antipyretic analgesics use and SARS-CoV-2 antibody titers following the second dose of the BNT162b2 mRNA vaccine: An observational study","volume":"41","author":"Inoue","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127892_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1242302","article-title":"Association between sleep duration and antibody acquisition after mRNA vaccination against SARS-CoV-2","volume":"14","author":"Izuhara","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127892_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2024.100489","article-title":"Reduction of adverse reactions and correlation between post-vaccination fever and specific antibody response across successive SARS-CoV-2 mRNA vaccinations","volume":"18","author":"Tani","year":"2024","journal-title":"Vaccine X"},{"key":"10.1016\/j.vaccine.2025.127892_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0269917","article-title":"Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine","volume":"17","author":"Kobashi","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127892_bb0235","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/vaccines10030451","article-title":"Systemic adverse effects induced by the BNT162b2 vaccine are associated with higher antibody titers from 3 to 6 months after vaccination","volume":"10","author":"Koike","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127892_bb0240","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3390\/jpm11060576","article-title":"Antibody response following a two-dose mRNA vaccination regimen, in health care workers of a tertiary hospital in athens, Greece","volume":"11","author":"Kontou","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.vaccine.2025.127892_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103805","article-title":"Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and na\u00efve healthcare workers","volume":"75","author":"Moncunill","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2025.127892_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.971277","article-title":"Predictors for reactogenicity and humoral immunity to SARS-CoV-2 following infection and mRNA vaccination: A regularized, mixed-effects modelling approach","volume":"14","author":"Williams","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127892_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975363","article-title":"COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19","volume":"13","author":"Heo","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127892_bb0260","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jiac.2023.09.025","article-title":"Association between use of antipyretics and antibody titers after two doses of the BNT162b2 SARS-CoV-2 vaccine in adolescents and young adults with underlying diseases","volume":"30","author":"Aiba","year":"2024","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.vaccine.2025.127892_bb0265","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3390\/diagnostics11071135","article-title":"Evaluation of anti-SARS-Cov-2 S-RBD IgG antibodies after COVID-19 mRNA BNT162b2 vaccine","volume":"11","author":"Lo Sasso","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.vaccine.2025.127892_bb0270","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/vaccines11020451","article-title":"Factors influencing antibody response to SARS-CoV-2 vaccination","volume":"11","author":"Kodde","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127892_bb0275","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3390\/vaccines10020316","article-title":"Intensity and dynamics of anti-SARS-CoV-2 immune responses after BNT162b2 mRNA vaccination: implications for public health vaccination strategies","volume":"10","author":"Speletas","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127892_bb0280","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.37908","article-title":"Association of symptoms after COVID-19 vaccination with anti-SARS-CoV-2 antibody response in the framingham heart study","volume":"5","author":"Hermann","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2025.127892_bb0285","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/jclinpath-2021-207572","article-title":"Antibody response and self-reported adverse reactions following vaccination with Comirnaty: a pilot study from a Croatian university hospital","volume":"75","author":"Lapi\u0107","year":"2022","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.vaccine.2025.127892_bb0290","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.vaccine.2022.01.002","volume":"40","author":"Uwamino","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127892_bb0295","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1093\/cid\/ciab381","article-title":"Age-dependent immune response to the biontech\/Pfizer BNT162b2 coronavirus disease 2019 vaccination","volume":"73","author":"M\u00fcller","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127892_bb0300","article-title":"Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study","volume":"10","author":"Naaber","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.vaccine.2025.127892_bb0305","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.3390\/vaccines10081220","article-title":"Correlation between adverse events and antibody titers among healthcare workers vaccinated with BNT162b2 mRNA COVID-19 vaccine","volume":"10","author":"Levy","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127892_bb0310","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/tan.15157","article-title":"Genome-wide association studies of response and side effects to the BNT162b2 vaccine in Italian healthcare workers: Increased antibody levels and side effects in carriers of the HLA-A*03:01 allele","volume":"102","author":"Magri","year":"2023","journal-title":"HLA"},{"key":"10.1016\/j.vaccine.2025.127892_bb0315","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000002337","article-title":"Adverse events & serological responses following SARS-CoV-2 vaccination in individuals with inflammatory bowel disease","author":"Markovinovi\u0107","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.vaccine.2025.127892_bb0320","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00915-21","article-title":"Correlation of immunogenicity and reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 vaccines","volume":"7","author":"Zhang","year":"2022","journal-title":"mSphere"},{"key":"10.1016\/j.vaccine.2025.127892_bb0325","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01930-y","article-title":"Correlates of neutralizing\/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals","volume":"11","author":"Maeda","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.127892_bb0330","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/vaccines10010015","article-title":"Factors associated with adverse reactions to BNT162b2 COVID-19 vaccine in a cohort of 3969 hospital workers","volume":"10","author":"Rivera-Izquierdo","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127892_bb0335","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3390\/vaccines9101089","article-title":"Association between reactogenicity and immunogenicity after vaccination with BNT162b2","volume":"9","author":"Bauernfeind","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127892_bb0340","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3390\/vaccines10030447","article-title":"Fever after vaccination against SARS-CoV-2 with mRNA-based vaccine associated with higher antibody levels during 6 months follow-up","volume":"10","author":"Kanizsai","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127892_bb0345","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2048559","article-title":"The association between adverse reactions and immune response against SARS-CoV-2 spike protein after vaccination with BNT162b2 among healthcare workers in a single healthcare system: a prospective observational cohort study","volume":"18","author":"Jubishi","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127892_bb0350","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2021.26.6.2100096","article-title":"Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021","volume":"26","author":"Abu Jabal","year":"2021","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2025.127892_bb0355","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41591-021-01325-6","article-title":"Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2","volume":"27","author":"Ebinger","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2025.127892_bb0360","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1056\/NEJMc2101667","article-title":"Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine","volume":"384","author":"Krammer","year":"2021","journal-title":"N Engl J Med"},{"issue":"e149154","key":"10.1016\/j.vaccine.2025.127892_bb0365","article-title":"One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19","volume":"131","author":"Levi","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2025.127892_bb0370","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1016\/j.vaccine.2024.03.030","article-title":"COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study","volume":"42","author":"Morgan","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127892_bb0375","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.vaccine.2021.11.090","article-title":"Prior COVID-19 infection is associated with increased Adverse Events (AEs) after the first, but not the second, dose of the BNT162b2\/Pfizer vaccine","volume":"40","author":"Raw","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127892_bb0380","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1001\/jama.2021.3341","article-title":"Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2","volume":"325","author":"Saadat","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2025.127892_bb0385","doi-asserted-by":"crossref","first-page":"7653","DOI":"10.1016\/j.vaccine.2022.10.073","article-title":"Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults","volume":"40","author":"Tompkins","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127892_bb0390","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1038\/s41467-022-31495-x","article-title":"SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection","volume":"13","author":"Wei","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.127892_bb0395","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127892_bb0400","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127892_bb0405","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1007\/s10067-022-06348-z","article-title":"Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients","volume":"41","author":"Pri-Paz Basson","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.vaccine.2025.127892_bb0410","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3390\/vaccines10081366","article-title":"Association of reactogenicity with immunogenicity of the ChAdOx1 nCoV-19 vaccine in patients undergoing hemodialysis","volume":"10","author":"Lin","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127892_bb0415","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3390\/vaccines9101209","article-title":"The COVID-19 mRNA BNT163b2 vaccine was well tolerated and highly immunogenic in young adults in long follow-up after haematopoietic stem cell transplantation","volume":"9","author":"Matkowska-Kocjan","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127892_bb0420","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.3390\/vaccines9121473","article-title":"Immunogenicity after second ChAdOx1 nCoV-19 (AZD1222) vaccination according to the individual reactogenicity, health status and lifestyle","volume":"9","author":"Choi","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127892_bb0425","doi-asserted-by":"crossref","DOI":"10.1515\/cclm-2023-0055","article-title":"Assessment of humoral and cellular immunity after bivalent BNT162b2 vaccination and potential association with reactogenicity","author":"Salvagno","year":"2023","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.vaccine.2025.127892_bb0430","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3390\/vaccines12040388","article-title":"Innate responses to the former COVID-19 vaccine candidate CVnCoV and their relation to reactogenicity and adaptive immunogenicity","volume":"12","author":"Wolz","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127892_bb0435","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab575","article-title":"Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers","volume":"9","author":"Coggins","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127892_bb0440","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.779212","article-title":"Anti-SARS-CoV-2 spike protein RBD antibody levels after receiving a second dose of ChAdOx1 nCov-19 (AZD1222) vaccine in healthcare workers: lack of association with age, sex, obesity, and adverse reactions","volume":"12","author":"Lee","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127892_bb0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257668","article-title":"Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?","volume":"16","author":"Takeuchi","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127892_bb0450","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.3390\/jcm10132844","article-title":"Systemic adverse events and use of antipyretics predict the neutralizing antibody positivity early after the first dose of ChAdOx1 coronavirus disease vaccine","volume":"10","author":"Park","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.vaccine.2025.127892_bb0455","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.molimm.2017.05.026","article-title":"Analysis of adipose tissue immune gene expression after vaccination of rainbow trout with adjuvanted bacterins reveals an association with side effects","volume":"88","author":"Veenstra","year":"2017","journal-title":"Mol Immunol"},{"key":"10.1016\/j.vaccine.2025.127892_bb0460","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3390\/vaccines10030439","article-title":"Short-term adverse events and antibody response to the BNT162b2 SARS-CoV-2 vaccine in 4156 health care professionals","volume":"10","author":"Azzolini","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127892_bb0465","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/vaccines11010182","article-title":"Adverse reactions after booster SARS-CoV-2 vaccination have less impact on antibody response than after basic vaccination scheme","volume":"11","author":"Kanizsai","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127892_bb0470","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2188\/jea.JE20220210","article-title":"Association between fever and antibody titer trends after a third dose of the mRNA-1273 vaccine","volume":"32","author":"Matsumoto","year":"2022","journal-title":"J Epidemiol"},{"key":"10.1016\/j.vaccine.2025.127892_bb0475","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.vaccine.2022.02.052","article-title":"Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine","volume":"40","author":"Yamamoto","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127892_bb0480","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.vaccine.2021.11.082","article-title":"Correlation of Anti-SARS-CoV-2 S1-specificIgG antibody levels and adverse events following vaccination with BNT162b2 mRNA COVID-19 vaccine in healthcare workers","volume":"40","author":"Izak","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127892_bb0485","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac493","article-title":"Correlation of postvaccination fever with specific antibody response to severe acute respiratory syndrome coronavirus 2 BNT162b2 booster and no significant influence of antipyretic medication","volume":"9","author":"Tani","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127892_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.micinf.2022.105044","article-title":"Factors influencing neutralizing antibody titers elicited by coronavirus disease 2019 vaccines","volume":"25","author":"Kung","year":"2023","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2025.127892_bb0495","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.vaccine.2023.01.050","article-title":"Association of a third vaccination with antibody levels and side reactions in essential workers: A prospective cohort study","volume":"41","author":"Hamada","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127892_bb0500","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3904\/kjim.2021.210","article-title":"Can reactogenicity predict immunogenicity after COVID-19 vaccination?","volume":"36","author":"Hwang","year":"2021","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.vaccine.2025.127892_bb0505","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jiac.2022.09.012","article-title":"Examining the association between vaccine reactogenicity and antibody titer dynamics after the third dose of BNT162b2 vaccine using a mixed-effects model","volume":"29","author":"Matsumoto","year":"2023","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.vaccine.2025.127892_bb0510","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/vaccines11010120","article-title":"Predictive value of reactogenicity for anti-SARS-CoV-2 antibody response in mRNA-1273 recipients: a multicenter prospective cohort study","volume":"11","author":"Choi","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127892_bb0515","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1080\/21645515.2016.1183077","article-title":"Effect of antipyretic analgesics on immune responses to vaccination","volume":"12","author":"Saleh","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127892_bb0520","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.3390\/vaccines10101608","article-title":"Association between adverse reactions and humoral immune response no longer detectable after BNT162b2 booster vaccination","volume":"10","author":"Bauernfeind","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127892_bb0525","article-title":"Correlation of adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations","author":"Cheng","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.vaccine.2025.127892_bb0530","series-title":"Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?","author":"Oyebanji","year":"2021"},{"key":"10.1016\/j.vaccine.2025.127892_bb0535","doi-asserted-by":"crossref","first-page":"60","DOI":"10.7774\/cevr.2023.12.1.60","article-title":"Humoral immune response to SARS-CoV-2 mRNA vaccines is associated with choice of vaccine and systemic adverse reactions","volume":"12","author":"Klingel","year":"2023","journal-title":"Clin Exp Vaccine Res"},{"key":"10.1016\/j.vaccine.2025.127892_bb0540","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3390\/vaccines9090977","article-title":"Occurrence of BNT162b2 vaccine adverse reactions is associated with enhanced SARS-CoV-2 IgG antibody response","volume":"9","author":"Rechavi","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127892_bb0545","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3349\/ymj.2022.0298","article-title":"Reactogenicity and immunogenicity of the ChAdOx1 nCOV-19 coronavirus disease 2019 vaccine in South Korean healthcare workers","volume":"63","author":"Hyun","year":"2022","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.vaccine.2025.127892_bb0550","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3390\/vaccines9121379","article-title":"Serum antibody response comparison and adverse reaction analysis in healthcare workers vaccinated with the BNT162b2 or ChAdOx1 COVID-19 vaccine","volume":"9","author":"Lim","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127892_bb0555","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3390\/vaccines12060665","article-title":"Association between reactogenicity and immunogenicity in a vaccinated cohort with two mRNA SARS-CoV-2 vaccines at a high-complexity reference hospital: a post hoc analysis on immunology aspects of a prospective cohort study","volume":"12","author":"S\u00e1ez-Pe\u00f1ataro","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127892_bb0560","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3390\/vaccines10040601","article-title":"Higher antibody concentrations in U.S. health care workers associated with greater reactogenicity post-vaccination","volume":"10","author":"Dickerson","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127892_bb0565","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.jiac.2022.05.009","article-title":"Effectiveness of the third dose of BNT162b2 vaccine on neutralizing Omicron variant in the Japanese population","volume":"28","author":"Kawasuji","year":"2022","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.vaccine.2025.127892_bb0570","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.2169\/internalmedicine.9699-22","article-title":"Association of systemic adverse reactions and serum SARS-CoV-2 spike protein antibody levels after administration of BNT162b2 mRNA COVID-19 vaccine","volume":"61","author":"Takahashi","year":"2022","journal-title":"Intern Med"},{"key":"10.1016\/j.vaccine.2025.127892_bb0575","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/labmed\/lmad044","article-title":"Reactogenicity and peak anti-RBD-S1 IgG concentrations in individuals with no prior COVID-19 infection vaccinated with different SARS-CoV-2 vaccines","volume":"55","author":"Milevoj Kopcinovic","year":"2024","journal-title":"Lab Med"},{"key":"10.1016\/j.vaccine.2025.127892_bb0580","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2323853","article-title":"Factors influencing adverse events following COVID-19 vaccination","volume":"20","author":"Villanueva","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127892_bb0585","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1080\/21645515.2015.1016670","article-title":"Factors associated with reported pain on injection and reactogenicity to an OMV meningococcal B vaccine in children and adolescents","volume":"11","author":"Petousis-Harris","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127892_bb0590","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3390\/vaccines9060579","article-title":"Predictive markers of immunogenicity and efficacy for human vaccines","volume":"9","author":"Van Tilbeurgh","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127892_bb0595","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00084-18","article-title":"Factors that influence the immune response to vaccination","volume":"32","author":"Zimmermann","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2025.127892_bb0600","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1016\/j.vaccine.2015.03.072","article-title":"Systems vaccinology: Enabling rational vaccine design with systems biological approaches","volume":"33","author":"Hagan","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127892_bb0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.04.026","article-title":"Metabolic phenotypes of response to vaccination in humans","volume":"169","author":"Li","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.127892_bb0610","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/s41590-022-01328-6","article-title":"Transcriptional atlas of the human immune response to 13 vaccines reveals a common predictor of vaccine-induced antibody responses","volume":"23","author":"Hagan","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2025.127892_bb0615","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41590-024-02036-z","article-title":"System vaccinology analysis of predictors and mechanisms of antibody response durability to multiple vaccines in humans","volume":"26","author":"Cortese","year":"2025","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2025.127892_bb0620","article-title":"Innovation in active and passive immunisation of people who are immunocompromised: a call to action","author":"Hill","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127892_bb0625","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56994-8","article-title":"Characterization of potential biomarkers of reactogenicity of licensed antiviral vaccines: randomized controlled clinical trials conducted by the BIOVACSAFE consortium","volume":"9","author":"Weiner","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2025.127892_bb0630","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.4732","article-title":"Expectations and prior experiences associated with adverse effects of COVID-19 vaccination","volume":"6","author":"Sch\u00e4fer","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2025.127892_bb0635","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(86)91044-5","article-title":"Frequency of true adverse reactions to measles-mumps-rubella vaccine: a double-blind placebo-controlled trial in twins","volume":"327","author":"Peltola","year":"1986","journal-title":"Lancet"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25011892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25011892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:26:15Z","timestamp":1781663175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25011892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":127,"alternative-id":["S0264410X25011892"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127892","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The relationship between the immunogenicity and reactogenicity of vaccines: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127892","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"127892"}}